Chronic Myeloid Leukaemia Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting chronic myeloid leukaemia clinical trials across 3 countries. Studies span Phase 2. Top locations include Moscow, Russia, Samara, Russia. Updated daily from ClinicalTrials.gov.


Chronic Myeloid Leukaemia Trials at a Glance

6 actively recruiting trials for chronic myeloid leukaemia are listed on ClinicalTrialsFinder across 2 cities in 3 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Moscow and Samara. Lead sponsors running chronic myeloid leukaemia studies include Australasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group (ALLG), and Samara State Medical University.

Browse chronic myeloid leukaemia trials by phase

Top cities for chronic myeloid leukaemia trials

About Chronic Myeloid Leukaemia Clinical Trials

Looking for clinical trials for Chronic Myeloid Leukaemia? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Myeloid Leukaemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Myeloid Leukaemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting

Chronic Myeloid Leukaemia: Treatment-Free Remission Registry

Chronic Myeloid Leukaemia
South Australian Health and Medical Research Institute (SAHMRI)100 enrolled1 locationACTRN12625000236493
Recruiting

Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib

Chronic Myeloid Leukaemia
Samara State Medical University105 enrolled2 locationsNCT05682924
Recruiting
Phase 2

CML14 (ASCENDANCE) - A study to assess efficacy of combination therapy with asciminib plus low dose dasatinib in newly diagnosed chronic phase Chronic Myeloid Leukaemia (CML) with high risk genetics

Chronic Myeloid Leukaemia (CML)
Australasian Leukaemia and Lymphoma Group (ALLG)100 enrolled15 locationsACTRN12623001338651
Recruiting
Phase 2

A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation

transformed AML/ MDSMyeloproliferative DisordersHodgkin's Disease+4 more
St Vincent's Hospital, Sydney127 enrolled10 locationsACTRN12622001232729
Recruiting
Phase 2

A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis

Non Hodgkin's Disease in remissionAcute Myeloid Leukaemia in first or second complete remissionacute Lymphoblastic Leukaemia in first or second complete remission+7 more
St Vincent's Hospital Sydney70 enrolled6 locationsACTRN12617000151336
Recruiting
Phase 2

Pilot cml autograft/glivec (STI571)/Intron A trial

Advanced phase chronic myeloid leukaemia
Australasian Leukaemia and Lymphoma Group48 enrolled1 locationACTRN12605000071628